



Eir Ventures

Eir Ventures' first "seedling" Synklino ApS completes oversubscribed DKK 106 million series A round.

Stockholm November 15. Synklino ApS today announced the closing of a heavily oversubscribed series A round amounting to DKK 106 million. The proceeds from the raise will be used for further development of the company's proprietary drug development platform to treat CMV infection, which significantly increases the risk of organ rejection and graft-versus-host disease (GVHD) in transplant patients. The successful capital raise speaks to the transformative impact of Eir Ventures' ability to seed finance early-stage projects and actively guide them to a meaningful inflection point which enables substantial third-party financing.

"We are very happy on behalf of transplant patients that we at Synklino can accelerate our drug development efforts. Eir Ventures' participation in our seed financing was instrumental for us to reach the confidence level needed of the incoming investors" says Dr Thomas Kledal CEO of Synklino

"It is delightful that Synklino can extend its efforts to help transplant patients. We are also glad we at Eir Ventures have enabled the progress from academic project to a financeable promising company by our participation as seed investors" says Dr Magnus Persson, Founding Partner at Eir Ventures and Director of the Board at Synklino.